Biochemical analyses of tissue from these mice suggest that treatment with a D2R agonist reduces tumour angiogenesis through increased apoptosis of tumour-associated endothelial cells, leading to a less favourable microenvironment for tumours and impeding cancer cell proliferation. Here, DRD2 is linked to neoplasm.